SynopsisFilgotinib is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. The global Filgotinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessin.....
SynopsisDecernotinib is a novel, potent, selective and orally available JAK3 inhibitor for the treatment of autoimmune diseases. The global Decernotinib (JAK3 Inhibitor) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, wi.....
SynopsisFedratinib is a selective inhibitor of JAK2.Fedratinib has potential antineoplastic activity. Fedratinib inhibits proliferation and induces apoptosis. The global Fedratinib market was valued at US$ million in 2023 and is anticipated to reach US$ million .....
SynopsisLestaurtinib inhibits JAK2, FLT3, and TrkA with IC50s of 0.9, 3, and less than 25 nM, respectively. Lestaurtinib is a multi-kinase inhibitor. It also has effective activity against the Trk family of receptor tyrosine kinases. The global Lestaurtinib mark.....
SynopsisGandotinib is identified as being highly selective for JAK2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders. The global Gandotinib market was valued at US$ million in 2023 and is anticipated to .....
Synopsis2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone (CAS 32384-65-9) is a synthetic building block which has been used to prepare C-glucosides via the nucleophilic addition of a suitably functionalised aryllithium reagent, followed by a triethylsilane reduction.....
SynopsisPacritinib is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. The global Pacritinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, .....
SynopsisUpadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fold selective for Jak1 over Jak2 in cellular assays dependent on specific, relevant cytokines. The global Upadacitinib market was valued at US$ million in 202.....
SynopsisMomelotinib, an aminopyrimidine derivative discovered by high-throughput enzyme and cell-based screening along with the optimization using structure-guided medicinal chemistry, is a potent and selective inhibitor of janus kinase 1 (JAK1), janus kinase 2 (JAK2).....
SynopsisOzanimod is a selective, orally available modulator of the sphingosine-1-phosphate (S1P) receptors S1P1 and SIP5. The global Ozanimod market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during .....
